The UNC Breast Cancer SPORE Tissue Procurement &Pathology Core (TPP) Facility is a multifunctional facility, comprised of two parts - Tissue Procurement and Translational Pathology. This Core provides centralized, quality controlled, quality assured procurement, processing, analysis, storage and distribution of normal and malignant breast tissue, blood specimens and other human specimens in support of basic science, translational, genomic, population and clinical trial cancer research. In addition to tissue and blood procurement services, the facility performs extraction of high quality DNA from whole blood, peripheral blood mononuclear cells, buccal smears and mouth rinses and immortalization of breast cancer patient lymphocytes. The Lineberger Data Warehouse (Core B), an Oracle-based, customized user-friendly database, operating on an honest broker model to protect identity and confidentiality, provides the infrastructure to monitor and survey each specimen and associated information. This provides a coordinated system of quality control, sample tracking and distribution of specimens to appropriate investigators. Both the procurement and utilization of breast cancer and control tissues increase substantially in 2010. Breast cancer-specific efforts that have and will support SPORE aims include centralized tissue and specimen banking, receipt and processing of breast-related human specimens including: freshly procured, snap-frozen and formalin fixed paraffin embedded (FFPE) block specimens, preparation of tissue microarrays (TMAs), cell microarrays, morphological evaluation and morphology-based assays (immunohistochemistry, immunofluorescence, in-situ hybridization, and fluorescence in-situ hybridization), assay development &training, and digital imaging and image analysis for spatial quantification of molecular analytes in intact specimens.
The UNC Breast SPORE has heavily integrated tissue and blood-based studies that require a high-performance Biospecimens/Pathology Core. These include high-volume analyses on FFPE tissues for population-based studies (Project 1), high complex analyses on fixed and frozen tissue from clinical trials (Project 3), and frozen tissue procurement and processing for lab-based translational studies (Projects 2, 4, and 5).
| Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336 |
| Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381 |
| McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297 |
| DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386 |
| Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194 |
| Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319 |
| Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32 |
| Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30 |
| Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7 |
| Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110: |
Showing the most recent 10 out of 598 publications
